Online inquiry

IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ517MR)

This product GTTS-WQ517MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Psoriasis, Organ transplant immunological rejection suppression research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ517MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ159MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ13228MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ5146MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ7437MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ13017MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ7469MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ3274MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ9752MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JR-141
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW